Hepatocellular carcinoma: Advances in systemic therapies [version 2; peer review: 2 approved, 1 approved with reservations]

Advanced hepatocellular carcinoma (HCC) is traditionally associated with limited treatment options and a poor prognosis. Sorafenib, a multiple tyrosine kinase inhibitor, was introduced in 2007 as a first-in-class systemic agent for advanced HCC. After sorafenib, a range of targeted therapies and imm...

詳細記述

書誌詳細

出版年:	F1000Research
主要な著者:	Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto, James Fung, Rex Wan-Hin Hui, Trevor Kwan-Hung Wu
フォーマット:	論文
言語:	英語
出版事項:	F1000 Research Ltd 2024-05-01
主題:	HCC Systemic therapy TKI ICI Liver Neoadjuvant eng
オンライン･アクセス:	https://f1000research.com/articles/13-104/v2